Staley Capital Advisers Inc. Purchases 3,700 Shares of SPDR S&P Biotech ETF $XBI

Staley Capital Advisers Inc. lifted its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 25.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,065 shares of the exchange traded fund’s stock after purchasing an additional 3,700 shares during the quarter. Staley Capital Advisers Inc.’s holdings in SPDR S&P Biotech ETF were worth $2,307,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Morgan Stanley boosted its position in shares of SPDR S&P Biotech ETF by 8.3% during the 4th quarter. Morgan Stanley now owns 11,491,683 shares of the exchange traded fund’s stock valued at $1,401,181,000 after acquiring an additional 882,718 shares in the last quarter. Wells Fargo & Company MN lifted its stake in SPDR S&P Biotech ETF by 75.7% during the fourth quarter. Wells Fargo & Company MN now owns 3,566,265 shares of the exchange traded fund’s stock worth $434,835,000 after purchasing an additional 1,536,122 shares during the period. Avoro Capital Advisors LLC bought a new position in SPDR S&P Biotech ETF during the fourth quarter worth about $256,053,000. Bessemer Group Inc. boosted its holdings in SPDR S&P Biotech ETF by 13.5% during the fourth quarter. Bessemer Group Inc. now owns 1,853,232 shares of the exchange traded fund’s stock valued at $225,965,000 after purchasing an additional 220,244 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in SPDR S&P Biotech ETF by 40.5% during the third quarter. Ameriprise Financial Inc. now owns 1,226,147 shares of the exchange traded fund’s stock valued at $122,906,000 after purchasing an additional 353,351 shares in the last quarter.

SPDR S&P Biotech ETF Trading Down 0.5%

XBI stock opened at $162.97 on Thursday. SPDR S&P Biotech ETF has a 1-year low of $84.39 and a 1-year high of $164.35. The business’s 50 day moving average is $139.15 and its 200-day moving average is $130.89. The firm has a market cap of $11.10 billion, a P/E ratio of 11.47 and a beta of 0.82.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.